Barclays’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.75M | Sell |
45,000
-178,500
| -80% | -$22.3M | ﹤0.01% | 1730 |
|
|
2025
Q4 | $27.3M | Buy |
223,500
+91,000
| +69% | +$10.4M | 0.01% | 1074 |
|
|
2025
Q3 | $13.3M | Buy |
132,500
+20,000
| +18% | +$1.8M | ﹤0.01% | 1475 |
|
|
2025
Q2 | $9.33M | Sell |
112,500
-175,000
| -61% | -$14M | ﹤0.01% | 1640 |
|
|
2025
Q1 | $23.3M | Sell |
287,500
-127,500
| -31% | -$11.4M | 0.01% | 957 |
|
|
2024
Q4 | $37.4M | Sell |
415,000
-500,000
| -55% | -$48.4M | 0.01% | 796 |
|
|
2024
Q3 | $90.4M | Buy |
+915,000
| New | +$89.9M | 0.02% | 464 |
|
|
2024
Q2 | – | Sell |
-420,100
| Closed | -$39.9M | – | 5354 |
|
|
2024
Q1 | $39.9M | Sell |
420,100
-155,000
| -27% | -$14.4M | 0.01% | 700 |
|
|
2023
Q4 | $51.4M | Buy |
+575,100
| New | +$42.7M | 0.02% | 652 |
|
|
2023
Q2 | – | Sell |
-778,800
| Closed | -$59.4M | – | 5131 |
|
|
2023
Q1 | $59.4M | Buy |
778,800
+686,800
| +747% | +$57M | 0.03% | 402 |
|
|
2022
Q4 | $7.64M | Buy |
+92,000
| New | +$7.45M | ﹤0.01% | 1352 |
|
|
2022
Q1 | – | Sell |
-115,700
| Closed | -$13M | – | 5695 |
|
|
2021
Q4 | $13M | Buy |
115,700
+110,000
| +1,930% | +$13.3M | ﹤0.01% | 1137 |
|
|
2021
Q3 | $716K | Buy |
5,700
+3,200
| +128% | +$412K | ﹤0.01% | 2985 |
|
|
2021
Q2 | $339K | Sell |
2,500
-220,000
| -99% | -$28.9M | ﹤0.01% | 3290 |
|
|
2021
Q1 | $30.2M | Sell |
222,500
-63,300
| -22% | -$9.48M | 0.02% | 628 |
|
|
2020
Q4 | $40.2M | Sell |
285,800
-201,400
| -41% | -$25.8M | 0.02% | 524 |
|
|
2020
Q3 | $54.3M | Buy |
487,200
+150,000
| +44% | +$16.8M | 0.03% | 375 |
|
|
2020
Q2 | $37.8M | Sell |
337,200
-571,500
| -63% | -$56.3M | 0.03% | 406 |
|
|
2020
Q1 | $70.4M | Buy |
908,700
+11,900
| +1% | +$1.05M | 0.06% | 229 |
|
|
2019
Q4 | $85.3M | Sell |
896,800
-13,200
| -1% | -$1.14M | 0.05% | 309 |
|
|
2019
Q3 | $69.4M | Sell |
910,000
-127,600
| -12% | -$10.6M | 0.04% | 346 |
|
|
2019
Q2 | $91M | Sell |
1,037,600
-242,500
| -19% | -$20.7M | 0.06% | 295 |
|
|
2019
Q1 | $116M | Buy |
1,280,100
+242,900
| +23% | +$20.7M | 0.08% | 196 |
|
|
2018
Q4 | $74.4M | Buy |
1,037,200
+328,100
| +46% | +$26.4M | 0.06% | 251 |
|
|
2018
Q3 | $68M | Sell |
709,100
-978,900
| -58% | -$94.9M | 0.05% | 305 |
|
|
2018
Q2 | $161M | Buy |
1,688,000
+1,028,100
| +156% | +$94.5M | 0.14% | 117 |
|
|
2018
Q1 | $57.9M | Sell |
659,900
-381,300
| -37% | -$34.8M | 0.04% | 365 |
|
|
2017
Q4 | $88.4M | Buy |
1,041,200
+344,600
| +49% | +$28.9M | 0.07% | 224 |
|
|
2017
Q3 | $60.3M | Sell |
696,600
-563,500
| -45% | -$45.2M | 0.06% | 249 |
|
|
2017
Q2 | $97.3M | Buy |
1,260,100
+896,600
| +247% | +$63.6M | 0.1% | 147 |
|
|
2017
Q1 | $25.2M | Buy |
363,500
+104,300
| +40% | +$7M | 0.03% | 468 |
|
|
2016
Q4 | $15.3M | Sell |
259,200
-158,500
| -38% | -$9.78M | 0.02% | 728 |
|
|
2016
Q3 | $27.7M | Buy |
417,700
+66,000
| +19% | +$4.08M | 0.03% | 420 |
|
|
2016
Q2 | $19M | Buy |
351,700
+263,300
| +298% | +$14.4M | 0.02% | 542 |
|
|
2016
Q1 | $4.51M | Sell |
88,400
-244,300
| -73% | -$12.7M | 0.01% | 1257 |
|
|
2015
Q4 | $23.3M | Buy |
332,700
+34,900
| +12% | +$2.38M | 0.03% | 518 |
|
|
2015
Q3 | $18.5M | Buy |
297,800
+78,500
| +36% | +$6.19M | 0.02% | 641 |
|
|
2015
Q2 | $18.4M | Buy |
219,300
+158,400
| +260% | +$12.3M | 0.02% | 688 |
|
|
2015
Q1 | $4.57M | Buy |
60,900
+34,500
| +131% | +$2.41M | 0.01% | 1635 |
|
|
2014
Q4 | $1.64M | Sell |
26,400
-20,100
| -43% | -$1.15M | ﹤0.01% | 2713 |
|
|
2014
Q3 | $2.4M | Buy |
46,500
+900
| +2% | +$45.9K | ﹤0.01% | 2509 |
|
|
2014
Q2 | $2.33M | Sell |
45,600
-38,400
| -46% | -$1.73M | ﹤0.01% | 2445 |
|
|
2014
Q1 | $3.98M | Buy |
84,000
+74,400
| +775% | +$3.81M | ﹤0.01% | 1891 |
|
|
2013
Q4 | $416K | Sell |
9,600
-5,400
| -36% | -$224K | ﹤0.01% | 4283 |
|
|
2013
Q3 | $645K | Buy |
15,000
+13,800
| +1,150% | +$559K | ﹤0.01% | 3827 |
|
|
2013
Q2 | $42K | Buy |
+1,200
| New | +$42.2K | ﹤0.01% | 6425 |
|
Other funds holding XBI
JFG
Barclays's XBI Position: Q1 2026 in Review
Barclays increased its State Street SPDR S&P Biotech ETF (XBI) stake by 50% in Q1 2026, buying an estimated $118M and bringing the position to 2,834,160 shares worth $362M. The position accounts for 0.09% of the portfolio, ranked #166.
Barclays first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $571M in Q2 2020. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Barclays held 2,834,160 shares of State Street SPDR S&P Biotech ETF worth $362M as of Q1 2026.
- Barclays bought 943,752 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $118M.
- State Street SPDR S&P Biotech ETF made up 0.09% of Barclays's portfolio in Q1 2026, its #166 holding.
- Barclays first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
- Barclays's State Street SPDR S&P Biotech ETF position peaked at $571M in Q2 2020.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.